Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial.

Background: The AspireAssist is the first Food and Drug Administration-approved endoluminal device indicated for treatment of class II and III obesity.

Objectives: We earlier reported 1-year results of the PATHWAY study. Here, we report 4-year outcomes.

Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial.

Objectives: The AspireAssist System (AspireAssist) is an endoscopic weight loss device that is comprised of an endoscopically placed percutaneous gastrostomy tube and an external device to facilitate drainage of about 30% of the calories consumed in a meal, in conjunction with lifestyle (diet and exercise) counseling.

Methods: In this 52-week clinical trial, 207 participants with a body-mass index (BMI) of 35.0-55.

Tonic and phasic pyloric activity in response to CCK-octapeptide.

Background: The purpose of this study was to determine whether a high-resolution solid-state catheter system could detect regional pressure changes within the antrum and pylorus in response to CCK-octapeptide.

Methods: Subjects received a 30 min infusion of CCK-octapeptide at either 0.02 or 0.